New stock news | Plai Pharmaceuticals plans to list on the Hong Kong stock market. The China Securities Regulatory Commission requires supplementary explanations on the compliance of overseas subsidiaries in foreign exchange management.

On June 5th, the China Securities Regulatory Commission issued the "Requirements for Supplementary Materials for Overseas Issuance and Listing (June 1st, 2026 - June 5th, 2026)". The International Department of the China Securities Regulatory Commission issued supplementary material requirements for 10 companies. Among them, Prili Pharmaceuticals was required to provide additional information on the specific implementation of overseas investments, foreign exchange management, and other regulatory procedures by its overseas subsidiaries. According to the Hong Kong Stock Exchange on February 13th, Prili Pharmaceuticals submitted a listing application to the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The China Securities Regulatory Commission asked Prili Pharmaceuticals to provide clarification on the following matters, and requested lawyers to verify and provide clear legal opinions: 1. Please provide supplementary information on the specific implementation of overseas investments, foreign exchange management, and other regulatory procedures by your overseas subsidiaries, and provide conclusive opinions on compliance. 2. Please provide supplementary information on the progress of identifying state-owned shareholders and the implementation of state-owned asset management procedures by your company. 3. Please provide supplementary information on the reasonableness of the prices at which new shareholders have entered your company in the past 12 months, and provide conclusive opinions on the existence of differences between these entry prices and whether there are issues such as improper benefit transfer. 4. Please provide supplementary information on the compliance of the equity incentive plan implemented by your company, including the specific composition of personnel, relationships between participating personnel and other shareholders, directors, supervisors, and senior management of the company, fairness of prices, agreement provisions, decision-making procedures, and operational compliance, and provide clear opinions on the legality and compliance of the plan and the existence of improper benefit transfer. 5. Please provide supplementary information on whether the shares held by shareholders participating in the "full circulation" this time are subject to pledges, freezes, or other defects in rights. The prospectus shows that Prili Pharmaceuticals is a leading innovative antimicrobial peptide (AMP) therapeutic drug company established in April 2009, focusing on four core therapeutic areas: anti-infection, metabolic diseases, tumors, and autoimmune diseases. The company is committed to addressing global unmet health needs through its proprietary breakthrough technologies and candidate drugs. As of the last feasible date, Prili Pharmaceuticals has nine candidate drugs, including a core product (PL-5) and two major products (PL-3301 and PL-18). According to Frost & Sullivan data, the company's core product PL-5 (pilocarpine) is the first pilocarpine class drug to have submitted a New Drug Application (NDA) globally. PL-3301 is a potential groundbreaking thermosensitive peptide gel for the treatment of oral candidiasis.